Increasing the production of chronic medicines during the covid 19 epidemic

GPO joins hands with domestic drug manufacturers Increasing the production of chronic medicines During the Covid-19 Pandemic

Dr. Witoon Danwiboon, Director of the Government Pharmaceutical Organization (GPO), said that due to the organization’s adjustments to the production plan of favipiravir (Favir drug) to increase and in this period It was found that the need for medications for chronic diseases increased more than usual as planned. It has an impact on the production line of chronic medicines. that the organization produces And on August 5th, a meeting was held to plan the country’s drug production in the situation of the Covid-19 epidemic. with the Food and Drug Administration (Drug Division), Pharmaceutical Organization Military Pharmaceutical Factory, Thai Red Cross Society and Thai Modern Medicine Manufacturing Association (TPMA) also attended the meeting. To plan and allocate the overall drug production capacity to be appropriate and sufficient to meet the needs of the country.

In the part of the organization, it is of the view that in order for patients with chronic diseases to have adequate medication continuously Therefore, it has asked for cooperation from the Thai Traditional Medicine Manufacturing Association, which takes care of private drug manufacturers in the country. Participated in the production of 7 chronic drugs, including: 1. Simvastatin. Simvastatin is used to reduce the levels of bad cholesterol and triglycerides in the blood vessels. Metformin, a drug used to treat diabetes

Losartan (Losartan) is used to lower blood pressure that works by causing blood vessels to dilate. 4. Propranolol (Propanolol) used to treat high blood pressure 5. Vitamin B1 6 12 6. Folic acid drug (Folic acid) to treat anemia from red blood cells. and folic acid deficiency 7. Fluoxetine Treatment of depression (Fluoxetine) and the drug Loratadine (Loratadine) to treat allergies, which the organization currently does not produce.

The seven drugs listed above are still being produced and reserved for patients during this transition period. and the organization has asked for cooperation Other private drug companies which has a registration of the aforementioned drug formula carry on more production which from the meeting The Thai modern pharmaceutical industry association is willing to plan together with other private drug companies to expedite production.

It was also found that some domestic drug companies have begun research and development of favipiravir. up some Which is gratifying to make Thailand more stable in the favipiravir sector.

“Favipiravir (Favir) production plan of the Government Pharmaceutical Organization. In August, the number of 2.5 million tablets, September increased to 23 million tablets, and from October onwards. The production will increase to at least 40 million per month, which will have management and reserves of favipiravir. Both from imported from abroad and produced by ourselves. enough to be consistent with the situation of the country’s COVID-19 outbreak.”

Dr. Mukdawan Assemble the Whitayakit Deputy Director of the Government Pharmaceutical Organization went on to say that the district office is not calm about the situation of the Covid-19 outbreak. and has planned to produce drugs in other medicines continuously And the GAO still insists on doing its duty with determination, dedication, carrying out all missions in medicine, vaccine and medical supplies for the people. And thank you to all sectors that have joined together to show their potential in hopes that Thailand can get through this crisis.